VolitionRx (NYSE:VNRX) Given Buy Rating at D. Boral Capital

VolitionRx (NYSE:VNRX)‘s stock had its “buy” rating reaffirmed by equities research analysts at D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports. They currently have a $5.00 target price on the stock.

A number of other analysts have also commented on the company. StockNews.com assumed coverage on VolitionRx in a research report on Friday. They issued a “sell” rating for the company. Benchmark restated a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd.

VolitionRx Stock Performance

NYSE VNRX opened at $0.62 on Tuesday. VolitionRx has a twelve month low of $0.43 and a twelve month high of $1.23. The stock has a market cap of $57.22 million, a PE ratio of -1.72 and a beta of 1.17. The firm has a 50-day simple moving average of $0.69 and a 200 day simple moving average of $0.67.

Hedge Funds Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC raised its position in shares of VolitionRx Limited (NYSE:VNRX) by 78.8% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,959 shares of the company’s stock after acquiring an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent quarter. 8.09% of the stock is owned by hedge funds and other institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.